pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Adempas
drug
save

riociguat

Marketedupdated 3mo ago
by Bayer HealthCare Pharmaceuticals Inc
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying riociguat

  • phase4Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPHterminatedn=30
  • phase3Riociguat in Children With Pulmonary Arterial Hypertension (PAH)active not recruitingn=24
  • phase2Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplastycompletedn=10
  • phase2Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAHterminatedn=35
  • phase3Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPHrecruitingn=15
  • phase4A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.completedn=18
  • phase2A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunctioncompletedn=202
  • phase2Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)completedn=22
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 4, 2026
113 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (20)

  • Feb 18, 2034compositionUS 10662188
  • Feb 18, 2034compositionUS 10662188
  • Feb 18, 2034compositionUS 10662188
  • Feb 18, 2034compositionUS 10662188
  • Feb 18, 2034compositionUS 10662188
  • Feb 18, 2034compositionUS 11203593
  • Feb 18, 2034compositionUS 11203593
  • Feb 18, 2034compositionUS 11203593
  • Feb 18, 2034compositionUS 11203593
  • Feb 18, 2034compositionUS 11203593
  • Feb 18, 2034formulationUS 12503469
  • Feb 18, 2034formulationUS 12503469
  • Feb 18, 2034formulationUS 12503469
  • Feb 18, 2034formulationUS 12503469
  • Feb 18, 2034formulationUS 12503469
  • Dec 4, 2026compositionUS 7173037113d
  • Dec 4, 2026compositionUS 7173037113d
  • Dec 4, 2026compositionUS 7173037113d
  • Dec 4, 2026compositionUS 7173037113d
  • Dec 4, 2026compositionUS 7173037113d

News(0)

no news has mentioned this drug yet

brand
Adempas
generic
riociguat
indication
Chronic Thromboembolic Pulmonary Hypertension
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 57m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?